Advertisement: Cambridge Enterprise mid banner
Advertisement: Simpsons Creative
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: China mid banner
Advertisement: Innova Systems
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: EBCam mid banner
Advertisement: Cambridge Network
Advertisement EY mid banner
Mid banner advertisement: BDO
Advertisement: RSM
Advertisement: Mogrify
24 January, 2020 - 20:41 By Tony Quested

RxCelerate takes 25,000 sq ft at Cambridge bio hub

Expanding life sciences business RxCelerate is moving its Cambridge HQ by taking 25,000 sq ft of prime office and lab space at BioMed Realty’s flagship research development at Babraham Research Campus. The deal means  [email protected] is is now 75 per cent let. 

RxCelerate CEO Dr jill Reckless is thrilled at the latest chapter in the company’s latest growth spurt at the heart of Cambridge’s world renowned technology hotspot. She said: “RxCelerate has experienced rapid expansion over the last five years, adding significant new services to our out-sourced drug R & D platform. 

“Our team, now in excess of 50, has outgrown our existing space, across several different buildings on the Babraham Research Campus so the opportunity to move our Cambridge UK headquarters into such a prestigious building on the same campus came at the perfect time for our business.” 

Executive chairman David Grainger added: “It’s a big moment for us – in six years we have grown from Jill and two staff in a single room to 25,000 sq ft premium space and a team of 60 – and we are still rapidly growing.

“Babraham Research Campus has always been a fantastic place to start new bioscience companies and it’s great to see this new development providing such high-quality space for those companies to expand without leaving their base. We are very excited to commence the next phase of our growth in our new home.”

In October 2017, BioMed Realty and the Babraham Research Campus launched a partnership creating 100,000 sq ft of research space for growing bioscience-based companies seeking to scale up their operations. 

[email protected] encompasses two adjacent buildings that will provide high quality research space for growing bioscience-based companies. 

Set to open as early as April 2020, the buildings are now 75 per cent pre-let, highlighting the booming life science community of academia, research institutions and industry.

Matt Smith, director, UK Market of BioMed Realty said: “BioMed Realty has been a part of Cambridge’s vibrant life science community since our acquisition of Granta Park in 2012 and we are very excited to continue the letting expansions at [email protected] with RxCelerate.

“The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise and we’re thrilled to welcome our expanding group of tenants to [email protected].”

As life sciences in the UK continues to thrive – the sector contributes over £70 billion to the UK economy and provides jobs for over 240,000 people across the country – [email protected] offers a unique space for the Cambridge life science innovation district to call home.

RxCelerate was founded in Cambridge in 2012 with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services.

The company operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.

RxCelerate offers a wide range of services. The biology team specialises in in vivo pharmacology, offering proprietary models of a wide range of human diseases, as well as complex cell-based assays. 

The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. 

A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.

• PHOTO: L-R – David Grainger, executive chairman of RxCelerate Group; Matt Smith, director UK for BioMed Really and Dr Jill Reckless, RxCelerate CEO

Newsletter Subscription

Stay informed of the latest news and features